<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134432</url>
  </required_header>
  <id_info>
    <org_study_id>AIHA-KA04062-gms</org_study_id>
    <nct_id>NCT01134432</nct_id>
  </id_info>
  <brief_title>Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia</brief_title>
  <official_title>Anti-CD20 Antibody Rituximab in Addition to Prednisolone in Treatment of Warm Antibody Related Autoimmune Hemolytic Anemia. A Randomised Danish Multicenter Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Copenhagen University Hospital at Herlev</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Copenhagen University Hospital at Herlev</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The conventional treatment in warm-antibody dependent autoimmune haemolytic anaemia (AIHA) is
      high-dose glucocorticoid, but in more than half of the patients, haemolytic activity will
      recur after end of treatment or during the gradual reduction in dose of the drug. As a
      result, many patients will finally be splenectomized or be treated with long-term
      glucocorticoids or other immunosuppressive drugs as azathioprine or cyclophosphamide. Recent
      studies have shown however, that some patients will respond to treatment with the chimeric
      anti-CD 20 antibody Rituximab and is some cases, the response is permanent. In most of the
      studies, Rituximab has been used in refractory disease or at least as second line treatment.
      In this study, patients with AIHA are randomized to receive either high-dose prednisolone
      with gradual reduction in dose over 2-3 months alone or in combination with Rituximab 375
      mg/m2 once a week for 4 weeks. The efficacy of Rituximab will be evaluated by a comparison of
      the patients in the two treatment arms. The primary treatment goal is a reduction in the
      number of patients who obtain long-term complete or partial remission. The secondary
      treatment goal is a reduction in patients who will be splenectomised or receive other
      immunosuppressive drugs. Finally a comparison of side effects of the treatments will take
      place.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients in each group in complete or partial remission</measure>
    <time_frame>End of treatment and follow-up for 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>End of treatment plus follow-up for 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Anemia, Hemolytic, Autoimmune</condition>
  <arm_group>
    <arm_group_label>Prednisolone + Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone + mabthera</intervention_name>
    <description>Prednisolone: 1,5 mg/kg for two weeks with gradually reduced dosis over two months.
Mabthera: 375 mg/m2 once a week for four weeks</description>
    <arm_group_label>Prednisolone + Rituximab</arm_group_label>
    <other_name>mabthera equals Rituximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone: 1,5 mg/kg for two weeks and then gradually reduced dosis over two months</description>
    <arm_group_label>Prednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or over

          -  Clinical and biochemical signs of haemolytic anaemia

          -  Positive Coombs test with anti-IgG on its own or with anti-CD3d

          -  Adequate contraceptive measures (intrauterine device, contraceptive pill or gestagen
             deposit) for women of childbearing potential

        Exclusion Criteria:

          -  Performance status &gt; 2

          -  Previous treatment with Rituximab

          -  Other immune suppressive or anti neoplastic treatment including prednisolone within 3
             months

          -  Auto immune haemolytic anaemia within 6 months

          -  Other serious disease

          -  Pregnant women and nursing mothers. Adequate contraceptive measures must be taken for
             the duration of the study.

          -  Contraindication for treatment with Rituximab, i.e. patients that develop
             hypersensitivity/allergy to the contents of the drug or have antibodies against murine
             proteins.

          -  Active infection which requires antibiotic treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik S Birgens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Haematology (L121), Copenhagen University Hospital Herlev</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet - Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Esbjerg Sygehus</name>
      <address>
        <city>Esbjerg</city>
        <zip>DK-6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haderslev Sygehus</name>
      <address>
        <city>Haderslev</city>
        <zip>DK-6100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haematology, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holstebro Sygehus</name>
      <address>
        <city>Holstebro</city>
        <zip>DK-7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naestved Sygehus</name>
      <address>
        <city>Naestved</city>
        <zip>DK-4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskilde Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>DK-4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viborg Sygehus</name>
      <address>
        <city>Viborg</city>
        <zip>DK-8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2010</study_first_submitted>
  <study_first_submitted_qc>June 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <last_update_submitted>September 9, 2013</last_update_submitted>
  <last_update_submitted_qc>September 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autoimmune hemolytic anemia</keyword>
  <keyword>hemolytic anemia</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Treatment of autoimmune hemolytic anemia</keyword>
  <keyword>warm antibody dependant autoimmune hemolytic anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

